Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Neurocrine Biosciences, Inc.

AstraZeneca vs. Neurocrine: R&D Spending Showdown

__timestampAstraZeneca PLCNeurocrine Biosciences, Inc.
Wednesday, January 1, 2014557900000046425000
Thursday, January 1, 2015599700000081491000
Friday, January 1, 2016589000000094291000
Sunday, January 1, 20175757000000121827000
Monday, January 1, 20185932000000160524000
Tuesday, January 1, 20195958000000200000000
Wednesday, January 1, 20205991000000275000000
Friday, January 1, 20219736000000328100000
Saturday, January 1, 20229762000000463800000
Sunday, January 1, 202310935000000565000000
Monday, January 1, 202413583000000731100000
Loading chart...

In pursuit of knowledge

Innovation in Pharmaceuticals: A Tale of Two Companies

In the ever-evolving world of pharmaceuticals, research and development (R&D) spending is a key indicator of a company's commitment to innovation. AstraZeneca PLC and Neurocrine Biosciences, Inc. have shown contrasting approaches over the past decade. From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, reflecting its robust investment in pioneering treatments. In contrast, Neurocrine Biosciences, Inc. increased its R&D spending by over 1,100%, albeit from a smaller base, highlighting its aggressive push into new therapeutic areas.

AstraZeneca's R&D expenditure consistently exceeded $5 billion annually, peaking at over $10 billion in 2023. Meanwhile, Neurocrine's spending grew from under $50 million in 2014 to over $500 million in 2023. This stark difference underscores the diverse strategies these companies employ to drive innovation and maintain competitive edges in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025